Business Wire

Carbon Trade eXchange (CTX) Partners With Victoria Falls Carbon Registry & Exchange in Zimbabwe: ‘Making Lemonade out of Lemons’

13.7.2023 20:49:00 EEST | Business Wire | Press release

Share

History was made in Victoria Falls Zimbabwe, on July 7th, 2023, the final day of the inaugural Africa Voluntary Carbon Credits Forum (AVCCM). Agreements were signed to initiate and install a Regional (Pan African) Carbon Registry owned and operated in Zimbabwe plus a locally operated, owned, and branded version of the worlds first and leading global Voluntary Carbon platform, Carbon Trade Exchange (CTX).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230713321840/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Contracts Signed in Victoria Falls Zimbabwe (Photo: Business Wire)

The Victoria Falls Carbon Registry (VFCR) will support the migration of Zimbabwe and other African nations projects and Carbon Credits back to Africa to be re-issued under their control. African Nations wishing to participate will be offered a National Sub-license and Registry Administration role within the VFCR, to support, lodge, monitor and manage projects and credit issuance in their nation. This low-cost solution negates the need for separate National Registries. Project types, methodologies and registry fees will be at the discretion of the VFCR, and they expect support from existing carbon credit standards internationally. The Registry will be operational in August 2023 and will start accepting projects, new or migrating, as soon as staff are trained to do so. Global Environmental Markets Group (GEM) will deliver the technology with training in August.

The Victoria Falls Carbon Exchange (VFCX) will have immediate access via CTX to hundreds of projects worldwide for buyers globally, millions of credits listed across worldwide for T+0 clearance and settlement. Plus new credits issued by VFCR Registry listed on the VFCX /CTX globally) instantly at the price the seller determines from that new registry. VFCX registry account holders can list via VFCX at no costs to list. A 5% fee on Sale of credits, no transfer or Retirement fees.

The AVCCM event attracted a large global audience across the carbon market, plus Government, banking, and project developers, supporting Zimbabwean Government’s decision to bring the carbon credits ‘home’ under the UNFCCC Paris Agreement.

“This is the future Africa said it wanted from the Paris agreement in 2015,” according to Wayne Sharpe, CEO & Founder, Global Environmental Markets Group. This follows on from COP27 where GEM and CTX did multiple presentations to various African nations. After speaking at the AVCCM event, Wayne added, “We saw the passion and commitments to Carbon Credits in Zimbabwe and Africa. This is why we built this technology, to deliver financial and ecological benefits to nations on the ground!

Kwanele Hlabangana, Chairman and Co-Founder of AVCCM said, “Partnering with experienced world class Carbon Market technology leaders like GEM & CTX is exciting. Responses from projects, communities and governments is outstanding. It's a great opportunity to accelerate Africa into the Global Climate to save our planet.” Ground up approach plus community engagement combined with GEM’s proven world class Registry and Exchange technology ticks the boxes for a trusted, credible, transparent, and vibrant African marketplace

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CTX/GEM:
Wayne Sharpe,
CEO and Founder
info@ctxglobal.com
+44 7502 229523,
www.ctxglobal.com
www.gemglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye